In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.

Presenters:

Angela Weyand, MD
Associate Professor, Pediatric Hematology Oncology
Co-Director, Combined Hematology/Gynecology Program
Pediatric Medical Director, Hemophilia Treatment Center
University of Michigan Medical School
Ann Arbor, Michigan

Guy Young, MD
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disease Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including: 

• Personal insights and examples of the process of SDM with patients with PV or ET
• How nuances of managing PV/ET influence SDM
• Individualizing the process of SDM
• Barriers to effective SDM
• Educational resources for patients with PV, ET, or MPNs
• Working with a team to incorporate SDM into clinical practice

Program faculty:

Joan How, MD
Scientific and Medical Consultant
Clinical Chief of Hematology
Brigham and Women's Faulkner Hospital
Associate Physician
Brigham and Women's Hospital
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Pankit Vachhani, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Alabama at Birmingham
O’Neal Comprehensive Cancer Center at the UAB
Birmingham, Alabama

Link to obtain CME/CE credit:
https://bit.ly/3ZtxWJm

Link to program page: 
https://bit.ly/3YQKlHb

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:

• Combination strategies
• Adverse event management
• Where CELMoD agents may best fit within current and future treatment strategies 

Presenters: 

Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California 

Niels van de Donk, MD, PhD
Professor of Hematology
Department of Hematology
Amsterdam UMC, Location VUmc
Amsterdam, Netherlands

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/4qvRwQM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:

• Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MF
• Abstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
• Abstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF
• Abstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDS
• Abstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDS
• Abstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDS

Presenter: 

Rami Komrokji, MD

Senior Member, Vice Chair
Section Head – Leukemia and MDS
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, Florida

Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

Link to full program: 
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).

Presenters:

John Heymach, MD, PhD
Chair and Professor
Department of Thoracic/Head and Neck Medical Oncology
Ruth Legett Jones Distinguished Chair
MD Anderson Cancer Center
Houston, Texas

Solange Peters, MD, PhD 
Professor and Director of Medical Oncology
Department of Oncology
University Hospital of Lausanne
Lausanne, Switzerland

Content based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Link to full program: 
https://bit.ly/3L1eksI

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:

• MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM 
• RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease
• CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics
• STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy
• CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM

Presenter:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Link to full program: 
https://bit.ly/4995nFA

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:

• CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL 
• BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLL
• BRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL 
• EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FL
• STARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCL

Presenter: 

Jeremy S. Abramson, MD, MMSc
Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Mass General Brigham Cancer Ins
Boston, Massachusetts

Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

Link to full program:
https://bit.ly/4aqMobZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: 

• LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
• Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapy
• Abstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infections
• Abstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand disease
• Abstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Presenter:
Hanny Al-Samkari, MD
The Peggy S. Blitz Endowed Chair in Hematology/Oncology
Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

Link to full program:
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:

• Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AML
• Abstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AML
• Abstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AML
• Abstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy
• Abstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CML
• Abstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKI

Presenter:
Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

Link to full program:
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

• TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan 
• TROP2 ADCS for patients with EGFR-mutated NSCLC
• TIGIT-targeting agents: domvanalimab, rilvegostomig

Presenters:

Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC

Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/4qZLR6B

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.